Duloxetine Hydrochloride + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Disorders
Conditions
Anxiety Disorders
Trial Timeline
Jan 1, 2005 → Mar 1, 2007
NCT ID
NCT00122863About Duloxetine Hydrochloride + placebo
Duloxetine Hydrochloride + placebo is a phase 3 stage product being developed by Eli Lilly for Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00122863. Target conditions include Anxiety Disorders.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673452 | Approved | Completed |
| NCT00536471 | Approved | Completed |
| NCT00422162 | Approved | Completed |
| NCT00408993 | Phase 3 | Completed |
| NCT00406848 | Approved | Completed |
| NCT00244296 | Approved | Completed |
| NCT00191919 | Phase 3 | Completed |
| NCT00122863 | Phase 3 | Completed |
| NCT00122824 | Phase 3 | Completed |
| NCT00190996 | Phase 3 | Completed |
| NCT00058968 | Phase 3 | Completed |
Competing Products
20 competing products in Anxiety Disorders